Feedback

Perfluorodecalin allows resuspension and prevents sediment solidification of extended-release drug formulations in primary packaging

ORCID
0000-0002-3569-5231
Affiliation
Midas Pharma GmbH Rheinstrasse 49 55218 Ingelheim am Rhein Germany
Primavessy, Daniel;
ORCID
0000-0003-1168-4682
Affiliation
Midas Pharma GmbH Rheinstrasse 49 55218 Ingelheim am Rhein Germany
Büttner, Sarah;
ORCID
0009-0007-1457-6886
Affiliation
Midas Pharma GmbH Rheinstrasse 49 55218 Ingelheim am Rhein Germany
Saaler-Reinhardt, Sigrid

Abstract In this technical note we show with two simple experiments how Perfluorodecalin (PFD), an injectable perfluorocarbon, can be used as an agent for resuspending microparticulate suspensions in primary packaging containers for injection. Furthermore, we explain how this can be a substantial improvement regarding patient compliance in comparison to the commonly used gas headspace for resuspension. Our experiments are conducted with poly(lactic-co-glycolic acid) particles (often used in extended-release pharmaceutical formulations for injection) and in primary packaging that is commonly used in injection devices (glass cartridges). The results show that our method is feasible for resuspension and moreover even sediment solidification/caking is reduced. The differences between the two datasets collected are statistically significant with p  < 0.01 in both cases. Graphical Abstract

Cite

Citation style:
Could not load citation form.

Access Statistic

Total:
Downloads:
Abtractviews:
Last 12 Month:
Downloads:
Abtractviews:

Rights

License Holder: © The Author(s) 2024

Use and reproduction: